Cantor Fitzgerald Analysts Give Amarin Corporation PLC (AMRN) a $10.00 Price Target

Cantor Fitzgerald set a $10.00 price objective on Amarin Corporation PLC (NASDAQ:AMRN) in a research report sent to investors on Monday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on the company. ValuEngine raised Amarin Corporation PLC from a sell rating to a hold rating in a research report on Saturday, November 4th. Zacks Investment Research downgraded Amarin Corporation PLC from a buy rating to a hold rating in a research report on Friday, November 3rd. HC Wainwright reissued a buy rating and set a $10.00 price target on shares of Amarin Corporation PLC in a research report on Thursday, November 2nd. Jefferies Group LLC reissued a buy rating on shares of Amarin Corporation PLC in a research report on Wednesday, October 11th. Finally, BidaskClub downgraded Amarin Corporation PLC from a sell rating to a strong sell rating in a research report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $7.75.

Shares of Amarin Corporation PLC (AMRN) opened at $3.46 on Monday. Amarin Corporation PLC has a twelve month low of $2.81 and a twelve month high of $4.47. The company has a quick ratio of 1.32, a current ratio of 1.63 and a debt-to-equity ratio of -1.48.

Amarin Corporation PLC (NASDAQ:AMRN) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $45.85 million. During the same quarter in the previous year, the company posted ($0.08) EPS. The business’s revenue was up 45.4% on a year-over-year basis. equities analysts anticipate that Amarin Corporation PLC will post -0.22 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Amarin Corporation PLC (AMRN) a $10.00 Price Target” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://stocknewstimes.com/2017/11/16/cantor-fitzgerald-analysts-give-amarin-corporation-plc-amrn-a-10-00-price-target.html.

In other news, insider Steven B. Ketchum sold 63,479 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 3.72% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Ameriprise Financial Inc. grew its position in shares of Amarin Corporation PLC by 0.9% in the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock valued at $1,266,000 after purchasing an additional 3,413 shares during the last quarter. Intrinsic Edge Capital Management LLC acquired a new position in shares of Amarin Corporation PLC in the second quarter valued at approximately $725,000. OxFORD Asset Management LLP grew its position in shares of Amarin Corporation PLC by 114.2% in the second quarter. OxFORD Asset Management LLP now owns 135,773 shares of the biopharmaceutical company’s stock valued at $547,000 after purchasing an additional 72,390 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Amarin Corporation PLC by 348.2% in the first quarter. Renaissance Technologies LLC now owns 1,730,200 shares of the biopharmaceutical company’s stock valued at $5,537,000 after purchasing an additional 1,344,200 shares during the last quarter. Finally, Perkins Capital Management Inc. grew its position in shares of Amarin Corporation PLC by 20.3% in the second quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 7,000 shares during the last quarter. 37.67% of the stock is currently owned by institutional investors.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply